Maria R. Baer

Also affiliated with Veterans Health Administration, U-M Rogel Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 20 papers. Top paper: “Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates”.

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Blood Advances(2022)10.1182/bloodadvances.2022008625

N/A

0.839DataRank · unranked

19 citations

Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock +35 more

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: Possible role of cytarabine

Leukemia Research(2008)10.1016/j.leukres.2007.11.006

N/A

0.457DataRank · unranked

20 citations

AnneMarie W. Block, Sheila N. Sait, Laurie A. Ford, Maurice Barcos, Maria R. Baer +1 more

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0091

N/A

0.216DataRank · unranked

3 citations

Ronan Swords, Ying Huang, Shelley Orwick, Daelynn R. Buelow, Nicole Abbott +23 more

PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-20-0663

N/A

0DataRank · unranked

26 citations

Prerna Singh, Christopher M. Bailey, Jonelle K. Lee, Shivani Kapoor, Rena G. Lapidus +7 more

PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers

Translational Oncology(2021)10.1016/j.tranon.2021.101283

N/A

0DataRank · unranked

14 citations

Rachel Abbotts, Christian Eberly, Mariusz Karbowski, Maria R. Baer, Tami J. Kingsbury +2 more

Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia

Journal of Oncology Pharmacy Practice(2021)10.1177/10781552211024727

N/A

0DataRank · unranked

12 citations

Bryan C. Hambley, Erin Hickey, Sarah Kashanian, Andrew Li, Maria R. Baer +11 more

Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication

Oncotarget(2021)10.18632/oncotarget.28042

N/A

0DataRank · unranked

3 citations

Shivani Kapoor, Eric S. Tvedte, Kshama A. Doshi, Ying Zou, Prerna Singh +8 more

Primary myelofibrosis in a patient with sickle cell disease

American Journal of Hematology(2021)10.1002/ajh.26347

N/A

0DataRank · unranked

1 citations

Zeba N. Singh, Maria R. Baer, Sarah E. Green

Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3729

N/A

0DataRank · unranked

58 citations

Aksinija A. Kogan, Søren M. Bentzen, Mi Tian, Rena G. Lapidus, Vu H. Duong +7 more

Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia

Proceedings of the National Academy of Sciences(2022)10.1073/pnas.2123227119

N/A

0DataRank · unranked

22 citations

Michael J. Topper, Anna J. Dellomo, Lora Stojanovic, Lena J. McLaughlin, T. Michael Creed +7 more

Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia

Leukemia(2020)10.1038/s41375-020-01080-6

N/A

0DataRank · unranked

36 citations

Bandish Kapadia, Dominique Bollino, Binny Bhandary, Maria R. Baer, Sandrine Niyongere +15 more

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

Leukemia(2023)10.1038/s41375-023-01846-8

N/A

0DataRank · unranked

74 citations

Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer +14 more

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Blood(2023)10.1182/blood-2023-187861

N/A

0DataRank · unranked

5 citations

Joseph G. Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Brian A. Jonas +7 more

Supplementary Tables and Figures from PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation

INDIGO (University of Illinois at Chicago)(2023)10.1158/1535-7163.22522443.v1

N/A

0DataRank · unranked

0 citations

Prerna Singh, Christopher M. Bailey, Jonelle K. Lee, Shivani Kapoor, Rena G. Lapidus +7 more

Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDS

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.11.08.622670

N/A

0DataRank · unranked

1 citations

Guillermo Urrutia, Andreas Due Ørskov, Hyeon Jin Kim, Seth A. Nelson, Anh Van Nguyen +20 more

Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies

Leukemia(2025)10.1038/s41375-024-02498-y

N/A

0DataRank · unranked

4 citations

Deedra Nicolet, Najla Alotaibi, Daelynn R. Buelow, Shelley Orwick, Charles T. Gregory +15 more

Use of Emergency Severity Index 2 reduces time to first analgesia in sickle cell disease vaso-occlusive crisis

Blood Advances(2025)10.1182/bloodadvances.2025016538

N/A

0DataRank · unranked

0 citations

Drupad Patel, Octavia Clopton, Maria R. Baer, Benoit Stryckman, R. Gentry Wilkerson +2 more

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study

Frontiers in Oncology(2022)10.3389/fonc.2022.858202

N/A

0DataRank · unranked

19 citations

Elizabeth M. Corley, Hanan Alharthy, Kathryn Kline, Jennie Y. Law, Seung‐Tae Lee +5 more

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions

Blood Cancer Discovery(2020)10.1158/0008-5472.bcd-19-0039

N/A

0DataRank · unranked

34 citations

Rossana Trotta, Lorenzo Stramucci, Justin J. Ellis, Jason G. Harb, Paolo Neviani +33 more

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions

Blood Cancer Discovery(2020)10.1158/2643-3249.bcd-19-0039

N/A

0DataRank · unranked

4 citations

Rossana Trotta, Lorenzo Stramucci, Justin J. Ellis, Jason G. Harb, Paolo Neviani +33 more